Many IVF programs are still relying heavily on judging an embryo’s potential to implant by how it looks under the microscope – essentially judging a book by its cover. But at RMANJ, our evidence-based approach demands we do more, and that is what comprehensive chromosome screening in NJ is all about.
RMANJ led the development of a one-of-a-kind, well validated, 24-chromosome screening process called SelectCCS which safely identifies whether embryos have a normal number of chromosomes (euploidy) or an abnormal number of chromosomes (aneuploidy). Since we now know genetic errors can occur with all 23 pairs of chromosomes, our screening process is comprehensive by counting all chromosomes at the molecular level and more accurate than previous testing processes that only count a handful of chromosomes.
Current data suggests that 50-70% of miscarriages are due to embryos with too few or too many chromosomes. At the same time we know that the frequency of aneuploidy increases with age. Using a more comprehensive and evidence-based approach like SelectCCS during the embryo selection process can improve safety and efficacy of your IVF cycle. SelectCCS has demonstrated to be 98% accurate in determining aneuploidy2,3.
“Advances in screening technology that allow us to rapidly and safely determine if an embryo is chromosomally normal now make ‘SET’ a more viable pathway to pregnancy for couples undergoing IVF. We can reduce the risk of twins, which tend to be more complicated pregnancies, but thanks to improved freezing technology not reduce the chance of having two children if that’s what a couple wants in the long run.”
Eric J. Forman, MD, FACOG, BEST Trial Investigator
In 2013 RMANJ donated SelectCCS to the Foundation for Embryonic Competence (FEC), a non-profit organization dedicated to improving outcomes and advancing knowledge in the areas of research, diagnosis, and education. SelectCCS is owned and operated by the Foundation for Embryonic Competence (www.feclabs.org).
1. Scott RT, Jr., Upham K, Forman E, Hong K, Scott K, Taylor D, Tao X, Treff NR. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilitzation implantation and delivery rates; a randomized controlled trial. Fertil Steril 2013. In Press.
2. Richard T. Scott Jr., M.D., Kathleen Ferry, B.S., Jing Su, M.S., Xin Tao, M.S., Katherine Scott, M.S., and Nathan R. Treff, Ph.D. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertility and Sterility. April 2012; 97(4):870-5.
3.Forman, E.J., Tao, X., Ferry, K.M., Taylor, D., Treff, N.R., Scott, R.T. Single Embryo Transfer with Comprehensive Chromosome Screening Results in Improved Ongoing Pregnancy Rates and Decreased Miscarriage Rates. Human Reproduction. April 2012; 27(4):1217-22.
Please note that a comparison of clinic success rates may not be meaningful because a patient’s medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic. We encourage you to learn more at www.sart.org.
Comprehensive chromosome screening (SelectCCS) in NJ helps provide effective fertility treatment in NJ. For more information, contact us or call 973-656-2089 today. You can also set up an appointment today.